Cargando…

Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia

Patients with tumor‐induced osteomalacia (TIO), an acquired paraneoplastic condition characterized by osteomalacia due to hypophosphatemia, exhibit a similar clinical picture to those with X‐linked hypophosphatemic rickets/osteomalacia (XLH). The human monoclonal anti‐fibroblast growth factor 23 (FG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imanishi, Yasuo, Ito, Nobuaki, Rhee, Yumie, Takeuchi, Yasuhiro, Shin, Chan Soo, Takahashi, Yutaka, Onuma, Hiroki, Kojima, Masahiro, Kanematsu, Masanori, Kanda, Hironori, Seino, Yoshiki, Fukumoto, Seiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988547/ https://www.ncbi.nlm.nih.gov/pubmed/32967046 http://dx.doi.org/10.1002/jbmr.4184

Ejemplares similares

Burosumab for the Treatment of Tumor‐Induced Osteomalacia
por: Jan de Beur, Suzanne M, et al.
Publicado: (2021)

Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies
por: Kubota, Takuo, et al.
Publicado: (2023)

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial
por: Insogna, Karl L, et al.
Publicado: (2019)

Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial
por: Namba, Noriyuki, et al.
Publicado: (2022)

First‐in‐Asian Phase I Study of the Anti‐Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X‐linked Hypophosphatemia
por: Cheong, Hae Il, et al.
Publicado: (2018)

Long-term use of burosumab for the treatment of tumor-induced osteomalacia
por: Crotti, C., et al.
Publicado: (2022)

Effects of burosumab on osteocalcin and bone mineral density in patient with 15-year history of nonremission tumor-induced osteomalacia initially treated with conventional therapy: Case report
por: Miyaoka, Daichi, et al.
Publicado: (2020)

Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thing
por: Jan de Beur, Suzanne M., et al.
Publicado: (2021)

Tumour-induced osteomalacia: 18 months of 2-weekly burosumab treatment
por: Aliberti, L, et al.
Publicado: (2023)

Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia
por: Amarnani, Raj, et al.
Publicado: (2020)

OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome
por: Jan De Beur, Suzanne, et al.
Publicado: (2019)

OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome
por: Carpenter, Thomas O, et al.
Publicado: (2020)

Favorable Effects of Burosumab on Fibroblast Growth Factor 23-Related Osteomalacia: A Case Report
por: Oe, Yuki, et al.
Publicado: (2021)

Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor: A case report
por: Oe, Yuki, et al.
Publicado: (2021)

Tumor-induced Osteomalacia Caused by a Parotid Tumor
por: Takashi, Yuichi, et al.
Publicado: (2017)

Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption
por: Hidaka, Naoko, et al.
Publicado: (2021)

Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia
por: Fukumoto, Seiji
Publicado: (2014)

Global guidance for the recognition, diagnosis, and management of tumor‐induced osteomalacia
por: Jan de Beur, Suzanne M., et al.
Publicado: (2022)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
por: Seino, Yutaka, et al.
Publicado: (2022)

Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor‐Induced Osteomalacia
por: Hartley, Iris R., et al.
Publicado: (2022)

Burosumab for X-linked hypophosphataemia
Publicado: (2021)

Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations
por: Kunz, Cornelia U., et al.
Publicado: (2016)

OR13-1 Long-Term Burosumab Therapy Provides Sustained Benefit in Patients with Tumor-Induced Osteomalacia: End of Study Findings From the Pivotal Phase 2 Study
por: Carpenter, Thomas, et al.
Publicado: (2022)

Localization of Oncogenic Osteomalacia by Systemic Venous Sampling of Fibroblast Growth Factor 23
por: Lee, Ji-Yeon, et al.
Publicado: (2017)

Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO)
por: Kinoshita, Yuka, et al.
Publicado: (2018)

A Case of Tumor-Induced Osteomalacia Detected by Venous Sampling
por: Horinouchi, Yasuo, et al.
Publicado: (2023)

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report
por: Takashi, Yuichi, et al.
Publicado: (2022)

The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer
por: de Boniface, Jana, et al.
Publicado: (2020)

Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases
por: Bosman, Ariadne, et al.
Publicado: (2022)

Osteomalacia
por: Fothergill, W. E.
Publicado: (1901)

Osteomalacia
Publicado: (1914)

Burosumab and Dental Abscesses in Children With X‐Linked Hypophosphatemia
por: Gadion, Margaux, et al.
Publicado: (2022)

Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur–uracil with CMF (N·SAS-BC 01 trial and CUBC trial)
por: Ohno, Shinji, et al.
Publicado: (2020)

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
por: Briot, Karine, et al.
Publicado: (2021)

SUN-525 Burosumab Experience In A UK Adolescent Population
por: Dharmaraj, Poonam, et al.
Publicado: (2019)

EUREKA study – the evaluation of real-life use of a biophotonic system in chronic wound management: an interim analysis
por: Romanelli, Marco, et al.
Publicado: (2017)

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
por: Oaknin, Ana, et al.
Publicado: (2023)

Osteomalacia in the Elderly
por: Sharland, D.E.
Publicado: (1982)

Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer
por: Ishiguro, Hiroshi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i60u4o5vpoiea6flp808r7a6fo